SCOTT S ZAMVIL

Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology SAN FRANCISCO, CA NPI 1720139348

General Payments — all program years on this page

$519,426.06

  • Category: General Payments
  • Program years: PY2018–2024
  • Record count: 479
  • As of (CMS publication): 2026-01-23

Latest program year (PY2024): $27,097.89 across 34 records · disputed records: 0

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How this figure is calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

Latest program year (PY2024) · sorted by reported total.

By paying entity

Latest program year (PY2024) · sorted by reported total.

By program year

Program yearAmountRecords
2018 $72,817.0450
2019 $136,437.79136
2020 $21,711.9022
2021 $69,916.9945
2022 $92,352.3799
2023 $99,092.0893
2024 $27,097.8934

Records — PY2024 (34)

Record IDPaying entityAmountDate Nature of paymentDispute statusPublishedSource
1087409968 Novartis Pharmaceuticals Corporation $29.21 01/09/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1087409970 Novartis Pharmaceuticals Corporation $46.86 01/25/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1087409972 Novartis Pharmaceuticals Corporation $119.39 03/07/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1087409974 Novartis Pharmaceuticals Corporation $24.70 03/27/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1087409976 Novartis Pharmaceuticals Corporation $15.90 06/06/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1087409978 Novartis Pharmaceuticals Corporation $34.87 06/11/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1087409980 Novartis Pharmaceuticals Corporation $10.57 08/21/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1093937763 Alexion Pharmaceuticals, Inc. $30.82 08/28/2024 Travel and Lodging Undisputed 01/23/2026 View at CMS
1093974476 Alexion Pharmaceuticals, Inc. $103.41 08/28/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1094009310 Alexion Pharmaceuticals, Inc. $3,550.00 08/28/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Undisputed 01/23/2026 View at CMS
1116221904 Amgen Inc. $34.03 02/28/2024 Travel and Lodging Undisputed 01/23/2026 View at CMS
1116221908 Amgen Inc. $3,250.00 02/28/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1116221913 Amgen Inc. $112.78 02/28/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1116221919 Amgen Inc. $25.00 02/28/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1116221922 Amgen Inc. $423.75 02/28/2024 Travel and Lodging Undisputed 01/23/2026 View at CMS
1116221928 Amgen Inc. $975.00 08/29/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Undisputed 01/23/2026 View at CMS
1117725167 Amgen Inc. $1,950.00 12/30/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Undisputed 01/23/2026 View at CMS
1136872991 TG Therapeutics, Inc. $47.67 07/01/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1139625972 GENZYME CORPORATION $58.00 02/29/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1139625998 GENZYME CORPORATION $89.83 04/14/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1139626050 GENZYME CORPORATION $39.78 09/17/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1139626072 GENZYME CORPORATION $24.75 11/12/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1139626074 GENZYME CORPORATION $15.05 11/13/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1139626076 GENZYME CORPORATION $24.46 11/11/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1139626080 GENZYME CORPORATION $124.63 11/12/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1139626082 GENZYME CORPORATION $2,894.00 11/12/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Undisputed 01/23/2026 View at CMS
1139626084 GENZYME CORPORATION $446.18 11/12/2024 Travel and Lodging Undisputed 01/23/2026 View at CMS
1139626086 GENZYME CORPORATION $39.69 11/12/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1139626088 GENZYME CORPORATION $8,038.00 11/12/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Undisputed 01/23/2026 View at CMS
1139626090 GENZYME CORPORATION $424.96 11/12/2024 Travel and Lodging Undisputed 01/23/2026 View at CMS
1139626092 GENZYME CORPORATION $1,195.10 11/12/2024 Travel and Lodging Undisputed 01/23/2026 View at CMS
1139626094 GENZYME CORPORATION $76.00 11/12/2024 Travel and Lodging Undisputed 01/23/2026 View at CMS
1139626096 GENZYME CORPORATION $33.50 11/12/2024 Travel and Lodging Undisputed 01/23/2026 View at CMS
1141552306 Merck Sharp & Dohme LLC $2,790.00 03/06/2024 Consulting Fee Undisputed 01/23/2026 View at CMS

Provenance & corrections

  • Dataset: CMS Open Payments — General Payments
  • Source: CMS Open Payments dataset (bulk file)
  • Publisher of source data: Centers for Medicare & Medicaid Services
  • Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.